LONDON (Alliance News) - Biotechnology company Epistem Holdings PLC on Thursday said its Indian distribution partner has now received a formal licence to import Epistem's tuberculosis and antibiotic resistance test to the country.
The licence has been granted for three years and will allow its partner, Xcelris Labs, to import Epistem's test. The pair will now start the process of preparing for the launch of the Genedrive kits.
"The Indian regulator's approval of our TB test represents a powerful endorsement of our strategy of developing Genedrive for infectious diseases and our continuing strengthening focus on the TB market. We are now focused on obtaining the support of Indian based KOL's to support the use and adoption of our device and assays," said Epistem Chief Executive Matthew Walls.
Shares in Epistem were up 0.4% to 318.70 pence on Thursday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
